Accessibility Menu
MoonLake Immunotherapeutics logo

MoonLake Immunotherapeutics

(NASDAQ) MLTX

Current Price$17.95
Market Cap$1.32B
Since IPO (2020)+71%
5 Year+78%
1 Year-63%
1 Month+1%

MoonLake Immunotherapeutics Financials at a Glance

Market Cap

$1.32B

Revenue (TTM)

$0.00

Net Income (TTM)

-$257.08M

EPS (TTM)

-$3.87

P/E Ratio

-4.62

Dividend

$0.00

Beta (Volatility)

0.57 (Low)

Price

$17.95

Volume

18,144

Open

$18.62

Previous Close

$17.95

Daily Range

$17.70 - $18.66

52-Week Range

$5.95 - $62.75

Estimated Earnings Date

Aug 4, 2026

About MoonLake Immunotherapeutics

Industry

Biotechnology

Employees

130

CEO

Jorge Santos da Silva, PhD

Headquarters

Zug, 6300, CH

MLTX Financials

Key Financial Metrics (TTM)

Gross Margin

0%

Operating Margin

0%

Net Income Margin

0%

Return on Equity

-78%

Return on Capital

-75%

Return on Assets

-64%

Earnings Yield

-21.65%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$1.32B

Shares Outstanding

73.62M

Volume

18.14K

Avg. Volume

991.07K

Financials (TTM)

Gross Profit

-$2.62M

Operating Income

-$244.83M

EBITDA

-$219.85M

Operating Cash Flow

-$196.01M

Capital Expenditure

-$35.00K

Free Cash Flow

-$196.04M

Cash & ST Invst.

$393.97M

Total Debt

$75.71M

MoonLake Immunotherapeutics Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

-$845.00K

N/A

Gross Margin

0.00%

N/A

Market Cap

$1.32B

N/A

Market Cap/Employee

$13.18M

N/A

Employees

100

N/A

Net Income

-$69.71M

-74.5%

EBITDA

-$69.18M

-72.9%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Net Cash

$257.12M

-36.4%

Accounts Receivable

$5.76M

+92.9%

Inventory

$0.00

N/A

Long Term Debt

$99.88M

+34.7%

Short Term Debt

$920.00K

-35.8%

Return on Assets

-64.21%

N/A

Return on Invested Capital

-75.47%

N/A

Free Cash Flow

-$66.29M

-73.6%

Operating Cash Flow

-$66.29M

-73.8%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
AVBPArriVent BioPharma, Inc. Common Stock
$30.35-8.28%
MBXMBX Biosciences, Inc. Common Stock
$30.28-2.04%
VTYXVentyx Biosciences, Inc.
$14.00+0.00%
ABSIAbsci Corporation
$6.40-12.81%

Trending Stocks

Symbol / CompanyPricePrice Chg
NOKNokia
$14.38-0.13%
TQQQProShares Trust - ProShares UltraPro Qqq
$73.05-0.14%
KEELKeel Infrastructure
$5.13-0.13%
SQQQProShares Trust - ProShares UltraPro Short Qqq
$43.19+0.14%

Questions About MLTX

What is the current price of MoonLake Immunotherapeutics?

MoonLake Immunotherapeutics is trading at $17.95 per share.

What is the 52-week range for MoonLake Immunotherapeutics?

Over the past 52 weeks, MoonLake Immunotherapeutics has traded between $5.95 and $62.75.

How much debt does MoonLake Immunotherapeutics have?

As of the most recent reporting period, MoonLake Immunotherapeutics reported total debt of $100.80M.

How much cash does MoonLake Immunotherapeutics have on hand?

MoonLake Immunotherapeutics reported $298.49M in cash and cash equivalents in its most recent financial results.

What is MoonLake Immunotherapeutics’s dividend yield?

MoonLake Immunotherapeutics does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.